RecruitingPhase 4NCT07185724

Ketorolac Use and Fresh Embryo Transfer Outcomes

Balancing Comfort and Success: Post-retrieval Ketorolac in Fresh Embryo Transfers


Sponsor

Jessica D. Kresowik

Enrollment

200 participants

Start Date

Nov 8, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Ketorolac is a medication often used to relieve pain after surgery. In the past, infertility doctors have been cautious about using ketorolac after egg retrieval for patients planning a fresh embryo transfer (usually done 5 days later). The concern was that ketorolac might increase the risk of bleeding or reduce the chances of the embryo implanting in the uterus. This concern comes from how ketorolac works-it blocks certain chemicals in the body (like prostaglandins and thromboxane) that help with blood clotting and play a role in early pregnancy. However, a large review of past studies found no real evidence that ketorolac increases bleeding risk. In fact, ketorolac is now routinely used for pain relief in IVF cycles where embryos are frozen and not transferred right away. More recent studies from Boston and Chapel Hill have shown that ketorolac provides better pain control and does not appear to harm IVF outcomes, even when embryos are transferred fresh (within the same cycle). Despite these encouraging findings, many IVF clinics still avoid using ketorolac during fresh cycles because of the theoretical concerns. That's why we need stronger, higher-quality research. This study aims to fill that gap by conducting a double-blind randomized controlled trial to find out whether giving ketorolac through an IV after egg retrieval affects important IVF outcomes-especially the chance of implantation and live birth-in patients undergoing fresh embryo transfers. Patients who choose to join the study will randomly be placed into one of two groups. One group will get ketorolac (a pain medicine) after an IVF egg retrieval. The other group will not get ketorolac after egg retrieval. Everything else in their IVF care will stay the same as it normally would. Primary outcome will be implantation rate following fresh embryo transfers in patients receiving ketorolac (30mg IV) vs no ketorolac for post-retrieval analgesia. Secondary outcomes will include pain scale, narcotics required, time to discharge, need for evaluation w/in 24 hours for pain/bleeding, clinical pregnancy rates, miscarriage rates, and live birth rates following fresh embryo transfers in patients receiving ketorolac vs no ketorolac for post-retrieval analgesia.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 37 Years

Inclusion Criteria4

  • IVF utilizing autologous oocytes and all sperm sources
  • IVF cycles utilizing ICSI and standard insemination
  • Plan to transfer embryo on day 5
  • BMI below 50

Exclusion Criteria1

  • allergies or medical contraindications to NSAIDs

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGKetorolac 30 mg IV

We will be evaluating the effect of post-oocyte retrieval ketorolac administration on clinical outcomes in fresh embryo transfer cycles.


Locations(1)

UI Health Care Center for Advanced Reproductive Care

Iowa City, Iowa, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07185724


Related Trials